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Total RNA for analysis was isolated using Trizol (Invitrogen). For reverse transcription and amplification, we use oligo(dT) primer and M-MLV reverse transcriptase (Life Technologies, Cergy Pontoise, France). Amplified product was separated through 2% agarose gel and visualized on an ultraviolet transilluminator.
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Results and discussion
Identification and characterization of NYD-SP8
In this study, a novel gene, NYD-SP8 (Gene bank Accession No. AY014285.1), was identified and characterized from cDNA microarray hybridization [7] . NYD-SP8 exhibited a 7-fold higher expression in adult testis than that in embryo testis (Fig. S1A) (Fig. S2) , which is important in converting plasminogen to active plasmin and promoting the degradation of ECM [9] . Once bound to uPAR, uPA is activated and turning on subsequent proteolytic cascades [10] , which have been implicated in cancer invasion and metastasis of a variety of cancers [11] . We thus raised the question: could it be possible that NYD-SP8 is involved in the uPA/uPAR-mediated ECM degradation during cancer metastasis?
To
answer this question, we employed a human hepatocellular carcinoma cell line (hHCC), which is highly invasive and does not have detectable endogenous NYD-SP8. We stably transfected
Fig. 1 Characterization of NYD-SP8 (A) RT-PCR analysis of NYD-SP8 mRNA expression levels in malignant lymphoma (1); adenocarcinoma of kidney (2); colon cancer (3); mastoncus (4); lung cancer (5); oesophageal cancer (6); gastric carcinoma (7); negative control (8). ␤-actin was used as internal control. (B) (i) Immunohistochemical demonstration of NYD-SP8 protein expression in multiple human cancer tissue arrays. (ii) Representative fields from (i) with various cancer tissues and their normal tissues counterparts: cervical cancer (1-2), pudendum cancer (3), colon cancer (4), lung
cancer (5), breast cancer (6) , oesophageal squamous cell carcinoma ESCC (7) (8) , normal colon mucosa (9) (10) ; normal oesophageal mucosa (11) (12) . (Fig. 1C) .
All photos were taken at 400ϫ. (C) (i) RT-PCR and (ii) Immunoblot of hHCC clones stably expressing NYD-SP8 (SP8) or empty vector (Vector).
NYD-SP8 (hHCC/SP8) or its vector control (hHCC/vector) into these cells. Expression of NYD-SP8 was confirmed by RT-PCR and Western blot
NYD-SP8 interacts with uPA/uPAR complexes and suppresses uPA activity
We then examined possible protein-protein interaction of NYD-SP8 with uPA/uPAR system by performing co-immunoprecipitation experiments. The results showed that NYD-SP8 could pull down both uPA and uPAR in hHCC/SP8 ( Fig. 2A-i (Fig. 2B-ii) . Interestingly, NYD-SP8 antibody, but not IgG, also produced an increase in uPA activity in a nasopharyngeal cancer cell line (CNE1) expressing endogenous NYD-SP8 (Fig. S3) , consistent with an inhibitory role of NYD-SP8 in the uPA/uPAR system. Similar results were observed using Western blot, with less active uPA detected in the NYD-SP8-expressing cells (Fig. 2C-i) and when excess recombinant NYD-SP8 was added (20 g/ml), active uPA production could also be blocked (Fig. 2C-ii) , consistent with that revealed by uPA activity assay (Fig. 2B-ii) . However, no significant alternations in pro-uPA and uPAR expression were observed (Fig 2C-i) (Fig. 2C-ii (Fig. 2D) (Fig. 3A- 
i). This was further confirmed by the use of recombinant NYD-SP8, showing significant reduction in both proand active MMP9 productions with 10 g/ml of NYD-SP8 used (Fig 3A-ii). To further assess the nature of NYD-SP8-induced suppression in MMP activities, mRNA expression of MMP2 and MMP9 was measured using semi-quantitative RT-PCR and the results
showed that both MMP2 and MMP9 mRNA levels were significantly decreased in hHCC/SP8 (Fig. 3A-iii Fig 3B-i) . However, there was no significant alternation in mRNA levels of cathepsin B (Fig. 3B-ii 
NYD-SP8 inhibits cancer cell invasion and metastasis in vitro and in vivo
To examine possible role of NYD-SP8 in suppressing cancer invasion/metastasis in vitro, matrigel invasion assay was performed. (Fig. 4B-i) . The results showed that hHCC/SP8 treated mice had 50% fewer lung micrometastasis than that of the vector control (Fig 4B-ii) . No significant difference in expression of human GAPDH was detected in the heart between hHCC/SP8 and hHCC/vector (Fig 4B-ii (Fig. 4C-i) . Figure 4C -ii and Fig. 4C-iii 
The results revealed that the invasion capacity of hHCC/SP8 cells was significantly lower by 60% as compared to the vector control (n ϭ 3, **P Ͻ 0.01, Fig. 4A). The NYD-SP8-reduced invasion capacity in vitro could be a result from inhibition of ECM degradation, because NYD-SP8 has potent effects on the three major classes of ECM-degrading proteases. To further demonstrate the inhibitory effect of NYD-SP8 on cancer invasion/metastasis in vivo, we injected hHCC/SP8 into
Fig. 2 NYD-SP8 interacts with uPA/uPAR complexes (A) Protein-protein interaction between NYD-SP8 and uPA/uPAR complexes. (i) 300 g of hHCC/SP8 cell lysate were immunoprecipitated (IP) with NYD-SP8 antibody (SP8), resolved by SDS-PAGE and immunoblotted (IB) with NYD-SP8, uPA or uPAR antibodies. (ii) Reversed co-immunoprecipitation of NYD-SP8 and uPA with uPAR. Antibodies for normal mouse or rabbit IgG were used as control correspondingly. (B) NYD-SP8 suppresses serine proteases uPA activity at protein level. (i) Comparison of the mean uPA activity in culture medium of hHCC/SP8 cell line (SP8) and its control (Vector), and reversal of uPA activity in the presence of 5 g/ml of NYD-SP8 antibody (SP8-Ab) but not the normal mouse IgG (SP8-IgG) (values are mean Ϯ S.D., n ϭ 3, ***P Ͻ 0.001). (ii) hHCC cells were treated with NYD-SP8 recombinant protein for 24 hrs at indicated concentrations, with corresponding concentrations of BSA as controls, and enzymatic activity of uPA in culture medium was measured. (Ϯ S.D., n ϭ 3, ***P Ͻ 0.001). (C) (i) Immunoblot analyses of expression pro-uPA, active uPA and uPAR in hHCC/SP8 cell line (SP8) or its control (Vector) (␤-tubulin as a loading control). (ii) hHCC cells were treated with NYD-SP8 recombinant protein for 24 hrs at indicated concentrations, with corresponding concentrations of BSA as controls, and cell lysate were subjected to immunoblot analyses with antibodies to uPA/uPAR complexes, active-uPA or to ␤-tubulin as a loading control (n ϭ 3). (D) RT-PCR analysis of mRNA expression of uPA, uPAR and PAI-1 in hHCC/SP8 cell line (SP8) or its control (Vector), with GAPDH as an internal control (n ϭ 3).
Fig. 3 In vitro inhibition of MMPs and cathepsin B activity. (A) NYD-SP8 suppresses MMPs at both transcriptional and protein level. (i) Representative zymographic analysis of active MMP2 and MMP9 release into conditioned media of hHCC/SP8 cell line (SP8) and its control (Vector) (n ϭ 3). Negative control lane (Ϫve) was loaded with conditioned media only. (ii) hHCC cells were treated with NYD-SP8 recombinant protein (SP8) for 24 hrs at indicated concentrations, with corresponding concentrations of BSA as controls, and representative zymographic analyses of MMP9 production conditioned medium are shown (n ϭ 6), indicating reduced pro-and active MMP9 with increasing NYD-SP8. (iii) RT-PCR analysis of mRNA expression MMP2 and MMP9 in hHCC/SP8 cells (SP8) or its control (Vector), with GAPDH as an internal control, showing reduced MMPs in hHCC/SP8 cells. (B) Suppressed
Fig. 4 Suppression of cancer invasion and metastasis in vitro and in vivo. (A) Summary of matrigel invasion assay showing reduced invasion of hHCC/SP8 cell line (SP8) as compared to control (Vector) after 48 hrs of incubation (Ϯ S.E.M., n ϭ 3, **P Ͻ 0.01). (B) NYD-SP8 suppresses experimental metastasis in vivo. (i) RT-PCR analysis of mRNA expression of human GAPDH (representing the amount of micro-metastasized human cancer cells) in the heart, lung and lymph node (L.N) of mice 60 days after i.p inoculation of hHCC/SP8 cell line (SP8) or its control (Vector
